Informational only — Not medical advice. Always consult a licensed healthcare provider.

Community data Updated 2 months ago
62.50 mg
Strip (10): ৳500.00 Box (3 × 10 = 30): ৳1,500.00
৳50.00 per tablet

Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.

All price changes →
From ৳50.00 per tablet
Available as: 62.50 mg · 3 x 10

More from Pulmoten

Other strengths and forms by Unimed Unihealth Pharmaceuticals Ltd.

Indications & Uses

Bosentan Monohydrate is used to treat pulmonary arterial hypertension (PAH). It helps improve exercise capacity and symptoms in patients with WHO functional class Ill. Efficacy has been shown in: Some improvements have also been shown in patients with PAH WHO functional class ll.

Pharmacology

Bosentan is a dual endothelin receptor antagonist (ERA), which means it binds to both endothelin A and B (ETA and ETB) receptors. It lowers both pulmonary and systemic vascular resistance. As a result, cardiac output goes up without any rise in heart rate. The neurohormone endothelin-1 (ET-1) is one of the most potent vasoconstrictors known. It can also promote fibrosis, cell proliferation, cardiac hypertrophy and remodelling, and it is pro-inflammatory. These effects happen when endothelin binds to ETA and ETB receptors in the endothelium and the vascular smooth muscle cells. ET-1 concentrations in tissues and plasma are raised in several cardiovascular disorders and connective tissue diseases, including pulmonary arterial hypertension, scleroderma, acute and chronic heart failure, myocardial ischaemia, systemic hypertension and atherosclerosis. This suggests that ET-1 plays a pathogenic role in these diseases. In pulmonary arterial hypertension and heart failure, when endothelin receptors are not blocked, high ET-1 concentrations are strongly correlated with how severe the disease is and with its prognosis.

Absorption: In healthy subjects, the absolute bioavailability of bosentan is approximately 50%, and food does not affect it. Maximum plasma concentrations are reached within 3 to 5 hours.

Distribution: Bosentan is highly bound (>98%) to plasma proteins, mainly albumin.

Elimination: The liver metabolises bosentan through the cytochrome P450 isoenzymes CYP2C9 and CYP3A4, and it is then removed by biliary excretion. Less than 3% of an oral dose is recovered in urine.

Dosage Reference

Reference Information Only

Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.

Adults:

Take the tablets by mouth, once in the morning and once in the evening. You can take them with or without food.

Pulmonary arterial hypertension: in adults, Bosentan treatment should start at 62.5 mg twice daily for 4 weeks. After that, the dose is increased to the maintenance dose of 125 mg twice daily.

For children aged 2 years or older, the optimal maintenance dose has not been defined in well-controlled studies. Paediatric pharmacokinetic data have shown, however, that Bosentan plasma concentrations in children were on average lower than in adult patients. Increasing the dose above 2 mg/kg body weight twice daily did not raise them.

Discontinuation of treatment: if the decision is taken to withdraw Bosentan, do it gradually while an alternative therapy is introduced.

Side Effects

Bosentan has been linked to dose-dependent rises in liver aminotransferases and falls in haemoglobin concentration. Other side effects include anaemia, a drop in haemoglobin, thrombocytopenia, neutropenia and leucopenia. Hypersensitivity reactions can also occur. People may get headache, syncope, palpitations, flushing or hypotension. Gastroesophageal reflux disease, diarrhoea, erythema, oedema and fluid retention are also listed. Aminotransferase elevations may come with hepatitis and/or jaundice. Liver cirrhosis and liver failure have been reported rarely.

Cautions & Contraindications

Warnings & Precautions

If pulmonary oedema occurs with Bosentan Monohydrate, think about stopping the treatment. Don't withdraw it suddenly. Lowering the dose first is worth considering (for example, half the dose for 3 to 7 days), because this reduces the risk of the patient's condition getting worse. Lactation. Bosentan Monohydrate may cause dizziness, which could affect the ability to drive or use machines.

Pregnancy & Breastfeeding

Bosentan must not be used in pregnancy. Nobody knows whether bosentan passes into human breast milk, so breast-feeding is not recommended while a woman is being treated with Bosentan.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Use in Special Populations

Dosage in hepatic impairment: patients with mild hepatic impairment need no dose adjustment. Bosentan Monohydrate is contraindicated in patients with moderate to severe liver dysfunction.

Dosage in renal impairment: no dose adjustment is required in patients with renal impairment, and the same applies to patients undergoing dialysis.

Dosage in elderly patients: no dose adjustment is required in patients over the age of 65 years.

Hepatic impairment: in patients with mildly impaired liver function (Child-Pugh class A), no relevant changes in the pharmacokinetics have been observed. The pharmacokinetics of Bosentan Monohydrate have not been studied in patients with Child-Pugh class B or C hepatic impairment, and the medicine is contra-indicated in this patient group.

Renal impairment: no dose adjustment is required in patients with renal impairment. There is no specific clinical experience in patients undergoing dialysis. Because of its physicochemical properties and the high degree of protein binding, bosentan is not expected to be removed from the circulation by dialysis to any significant extent.

Storage

Keep Bosentan Monohydrate below 30°C, in a cool and dry place, away from light. Keep it out of children's reach.

Drug Interactions

Open checker →
Moderate Fluconazole
Moderate Lovastatin
Moderate Rifampicin
Moderate Sildenafil
Moderate Tadalafil
Moderate Tacrolimus
Moderate Simvastatin
Moderate Warfarin Sodium
Moderate Ritonavir
Moderate Ketoconazole

Common questions about Pulmoten 62.50 mg

What is Pulmoten 62.50 mg Tablet?

Pulmoten 62.50 mg Tablet is a medicine that contains Bosentan Monohydrate. It is made by Unimed Unihealth Pharmaceuticals Ltd. It belongs to the Anti-hypertensive group of medicines.

What is Pulmoten used for?

Bosentan Monohydrate is used to treat pulmonary arterial hypertension (PAH). It helps improve exercise capacity and symptoms in patients with WHO functional class Ill.

What are the side effects of Pulmoten?

Bosentan has been linked to dose-dependent rises in liver aminotransferases and falls in haemoglobin concentration. Other side effects include anaemia, a drop in haemoglobin, thrombocytopenia, neutropenia and leucopenia.

Can I take Pulmoten during pregnancy or while breastfeeding?

Bosentan must not be used in pregnancy. Nobody knows whether bosentan passes into human breast milk, so breast-feeding is not recommended while a woman is being treated with Bosentan. Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

How should I store Pulmoten?

Keep Bosentan Monohydrate below 30°C, in a cool and dry place, away from light. Keep it out of children's reach.

Can I take other medicines with Pulmoten?

Some medicines can interact with Bosentan Monohydrate, for example: Fluconazole, Lovastatin, Diltiazem Hydrochloride, Rifampicin, Amiodarone Hydrochloride, Sildenafil. Tell your doctor or pharmacist about every medicine you take.

Is there a cheaper medicine with the same ingredient?

Pulmoten is already among the lowest-priced brands of Bosentan Monohydrate at this strength.

Do I need a prescription for Pulmoten?

Pulmoten is a prescription (Rx) medicine. Take it as your doctor advises.

Last updated: 20 Aug 2026